Effects of orally administered interferon-? on the pathogenesis of feline leukaemia virus-induced erythroid aplasia

Kociba, Gary J.; Garg, Ramesh C.; Khan, Kanwar Nasir M.; Reiter, J. A.; Chatfield, R. C.

doi:10.1007/bf00638923

Cited by 8 publications

(9 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This body of evidence is drawn from studies involving IFN-α, an antiviral cytokine that has been extensively studied in animal and human subjects 22–25,33–36. IFN-α activates natural killer lymphoid cells, and has been demonstrated effective in extremely small concentrations 26,28.…”

Section: Ofalt and Galt: Implications For The Elbw Infantmentioning

confidence: 99%

“…For many years it was assumed that an orally administered cytokine, such as IFN-α, would not be efficacious because of proteolysis in the gastrointestinal tract 27. However, research with animals33–36 and adult humans22–25 has demonstrated that orally administered IFNs have potent antiviral activity,36 can exert both local and systemic effects, and yet be nearly undetectable in the serum43 with often no more than 1% of the administered dose recovered in serum samples 44,45. Colostral cytokines likely remain stable in the gastrointestinal tract of infants, as they appear to escape proteolysis in the immature gastrointestinal tract of the ELBW infant 46–48.…”

Section: Ofalt and Galt: Implications For The Elbw Infantmentioning

confidence: 99%

“…Similarly, in mice with encephalitis and multiple sclerosis, the oral administration of low dose IFN-α/-β was shown to decrease CNS inflammation and decrease the secretion of pro-inflammatory cytokines IL-2 and IFN-γ 52. Veterinarians and researchers have administered IFN-α orally for many years, and have noted efficacy in the treatment of viral, bacterial and parasitic infections in larger animals such as cats, cattle, swine and horses 33–36…”

Section: Ofalt and Galt: Implications For The Elbw Infantmentioning

confidence: 99%

See 2 more Smart Citations

Oropharyngeal administration of colostrum to extremely low birth weight infants: theoretical perspectives

et al. 2008

View full text Add to dashboard Cite

Section: Ofalt and Galt: Implications For The Elbw Infantmentioning

confidence: 99%

Section: Ofalt and Galt: Implications For The Elbw Infantmentioning

confidence: 99%

Section: Ofalt and Galt: Implications For The Elbw Infantmentioning

confidence: 99%

See 1 more Smart Citation

Oropharyngeal administration of colostrum to extremely low birth weight infants: theoretical perspectives

et al. 2008

View full text Add to dashboard Cite

“…Regarding the use of IFNs in FeLV-and FIV-associated diseases, some studies showed encouraging and sometimes dramatic therapeutic effects on symptomatic as well as asymptomatic cats, [11][12][13][14][15] whereas other more recent studies failed to confirm previous observations. 16,17 The discrepancies may be attributed, at least in part, to different study designs, notably regarding (sub)types of IFN, species of origin, purity of preparations, treatment route, dosage, and schedule, as well as the age and pathological stage of FeLVinfected cats.…”

mentioning

confidence: 99%

Therapeutic Effects of Recombinant Feline Interferon-ω on Feline Leukemia Virus (FeLV)-Infected and FeLV/Feline Immunodeficiency Virus (FIV)-Coinfected Symptomatic Cats

et al. 2004

View full text Add to dashboard Cite

The clinical efficacy of a recombinant feline interferon, rFeIFN-omega, was evaluated for the treatment of cats presented with clinical signs associated with feline leukemia virus (FeLV) infection and FeLV/feline immunodeficiency virus (FIV) coinfection in the field. In this multicentric, double-blind, placebo-controlled trial, 81 cats meeting the inclusion criteria were randomly placed into 2 groups and treated subcutaneously with rFelFN-omega (1 million [M]U/kg per day) or placebo once daily for 5 consecutive days in 3 series (day 0, 14, 60). The cats were monitored for up to 1 year for clinical signs and mortality. During the initial 4-month period, interferon (IFN)-treated cats (n = 39) had significantly reduced clinical scores compared with placebo (n = 42), with all cats having received concomitant supportive therapies. Compared with the control, the IFN-treated group showed significantly lower rates of mortality: 39% versus 59% (1.7-fold higher risk of death for controls) at the 9-month time point and 47% versus 59% (1.4-fold higher risk of death for controls) at the 12-month time point. The IFN treatment was associated with minor but consistent improvement in abnormal hematologic parameters (red blood cell count, packed cell volume, and white blood cell count), apparently underlying the positive effects of IFN on clinical parameters. These data demonstrate that rFeIFN-omega initially has statistically significant therapeutic effects on clinical signs and later on survival of cats with clinical signs associated with FeLV infection and FeLV/FIV coinfection.

show abstract

“…16,17 The discrepancies may be attributed, at least in part, to different study designs, notably regarding (sub)types of IFN, species of origin, purity of preparations, treatment route, dosage, and schedule, as well as the age and pathological stage of FeLVinfected cats.…”

mentioning

confidence: 99%

Therapeutic Effects of Recombinant Feline Interferon‐co on Feline Leukemia Virus (FeLV)‐Infected and FeLV/Feline Immunodeficiency Virus (FIV)‐Coinfected Symptomatic Cats

Mari

Maynard

Sanquer

et al. 2004

Veterinary Internal Medicne

View full text Add to dashboard Cite

The clinical efficacy of a recombinant feline interferon, rFeIFN-, was evaluated for the treatment of cats presented with clinical signs associated with feline leukemia virus (FeLV) infection and FeLV/feline immunodeficiency virus (FIV) coinfection in the field. In this multicentric, double-blind, placebo-controlled trial, 81 cats meeting the inclusion criteria were randomly placed into 2 groups and treated subcutaneously with rFeIFN-(1 million [M]U/kg per day) or placebo once daily for 5 consecutive days in 3 series (day 0, 14, 60). The cats were monitored for up to 1 year for clinical signs and mortality. During the initial 4-month period, interferon (IFN)-treated cats (n ϭ 39) had significantly reduced clinical scores compared with placebo (n ϭ 42), with all cats having received concomitant supportive therapies. Compared with the control, the IFN-treated group showed significantly lower rates of mortality: 39% versus 59% (1.7-fold higher risk of death for controls) at the 9-month time point and 47% versus 59% (1.4-fold higher risk of death for controls) at the 12-month time point. The IFN treatment was associated with minor but consistent improvement in abnormal hematologic parameters (red blood cell count, packed cell volume, and white blood cell count), apparently underlying the positive effects of IFN on clinical parameters. These data demonstrate that rFeIFN-initially has statistically significant therapeutic effects on clinical signs and later on survival of cats with clinical signs associated with FeLV infection and FeLV/FIV coinfection.

show abstract

Effects of orally administered interferon-? on the pathogenesis of feline leukaemia virus-induced erythroid aplasia

Cited by 8 publications

References 8 publications

Oropharyngeal administration of colostrum to extremely low birth weight infants: theoretical perspectives

Oropharyngeal administration of colostrum to extremely low birth weight infants: theoretical perspectives

Therapeutic Effects of Recombinant Feline Interferon-ω on Feline Leukemia Virus (FeLV)-Infected and FeLV/Feline Immunodeficiency Virus (FIV)-Coinfected Symptomatic Cats

Therapeutic Effects of Recombinant Feline Interferon‐co on Feline Leukemia Virus (FeLV)‐Infected and FeLV/Feline Immunodeficiency Virus (FIV)‐Coinfected Symptomatic Cats

Contact Info

Product

Resources

About